SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma rises on getting USFDA’s tentative approval for Trabectedin for Injection

18 Aug 2022 Evaluate

Natco Pharma is currently trading at Rs. 659.70, up by 8.40 points or 1.29% from its previous closing of Rs. 651.30 on the BSE.

The scrip opened at Rs. 663.95 and has touched a high and low of Rs. 669.00 and Rs. 657.50 respectively. So far 9139 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 993.45 on 06-Sep-2021 and a 52 week low of Rs. 607.95 on 31-May-2022.

Last one week high and low of the scrip stood at Rs. 684.85 and Rs. 636.70 respectively. The current market cap of the company is Rs. 11889.95 crore.

The promoters holding in the company stood at 48.80%, while Institutions and Non-Institutions held 26.95% and 24.25% respectively.

Natco Pharma has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis ) for the 1mg/vial presentation. According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1194.80 20.80 (1.77%)
11-May-2026 13:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1873.30
Dr. Reddys Lab 1294.70
Cipla 1321.65
Zydus Lifesciences 948.60
Lupin 2276.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×